Effect of Low-dose Intracoronary Reteplase on Myocardial Infarct Size During Primary Percutaneous Coronary Intervention

NCT04571580 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

36

Enrollment

OTHER

Sponsor class

Stopped The study enrollment is slow due to the pandemic.

Conditions

Acute ST-segment Elevation Myocardial Infarction

Interventions

DRUG: Normal Saline
DRUG: Reteplase Injection 9mg
DRUG: Reteplase Injection 18mg

Sponsor

Ge Junbo